Clinical Trials Browser

Recruiting × spartalizumab × Head & Neck × Clear all

NCT04080804 2026-02-09

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06475300 2026-01-21

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase 2 Recruiting

Head & NeckThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT05941507 2025-09-24

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Phase 1/2 Recruiting

BreastCNSGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06802835 2025-05-16

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT06437522 2025-05-07

A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04830267 2024-03-28

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT06170710 2023-12-14

Postoperative CCRT Followed by Immunotherapy in High-Risk LA HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05213884 2023-05-06

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05342792 2022-04-25

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma

NCT04778956 2021-03-04

Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma

Phase 3 Recruiting

Nasopharyngeal Carcinoma, Recurrence